Stocktoria
Kenvue Inc. KVUE
Kenvue Inc. (KVUE) earns a Piotroski F-score of 5/9 (mixed financial health), with an Altman Z″ in the grey zone. It pays a dividend yielding 4.30% (safety: at-risk). FY2025 revenue was $15.1B at a 9.7% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Beneish M-score: -2.47 — low (below −2.22 — no manipulation red flag) . A statistical screen for earnings manipulation, not proof — and it doesn't apply to most banks/insurers.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-08-11 | UBS | Neutral (main) |
| 2026-07-21 | Barclays | Equal-Weight (main) |
| 2026-07-16 | UBS | Neutral (main) |
| 2026-04-15 | Citigroup | Neutral (main) |
| 2026-04-14 | Barclays | Equal-Weight (main) |
| 2026-04-07 | UBS | Neutral (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Forward estimates · earnings calendar →
Consensus analyst estimates and scheduled dates — forward-looking, may change.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 5/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · grey zone
| Component | Value |
|---|---|
| Working capital / assets | -0.009 |
| Retained earnings / assets | -0.008 |
| EBIT / assets | 0.089 |
| Equity / liabilities | 0.66 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| KVUE | Kenvue Inc. | 5/9 | 1.21 | 25 | -2.1% |
| EL | ESTEE LAUDER COMPANIES INC | 4/9 | 2.44 | — | -8.2% |
| CL | COLGATE PALMOLIVE CO | 4/9 | 6.23 | 34.6 | +1.4% |
| COTY | COTY INC. | 5/9 | -1.14 | — | -3.7% |
| EPC | EDGEWELL PERSONAL CARE Co | 5/9 | 2.61 | 50.3 | -1.3% |
| ELF | e.l.f. Beauty, Inc. | 3/9 | 2.18 | 152.3 | +24.6% |
| IPAR | INTERPARFUMS INC | 5/9 | 8.09 | 20.5 | +2.5% |
About Kenvue Inc.
Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates in three segments: Self Care, Skin Health and Beauty, and Essential Health. The company offers over-the-counter medicine for cough, cold and allergy, pain care, digestive health, smoking cessation, and eye care, as well as other naturally inspired and self-care products, digital diagnostics, and telemedicine; face and body care, hair, sun, and other care products; oral and baby care, women's health, wound care, and other essential health products; tampons; cosmetics; and vitamins and supplements. It sells its products under the Benadryl, Calpol, Motrin, Nicorette, Rhinocort, Tylenol, Zarbee's Naturals, and Zyrtec; Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Neutrogena, OGX, and Rogaine; BAND-AID, Carefree, Desitin, Johnson's, Listerine, o.b., and Stayfree; and ORSL, Clean & Clear, Versalie, Benylin, Daktarin, Imodium, Johnson's Baby, Johnson's Adult, Maui Moisture, Microlax, Motilium, Neosporin, Neostrata, Pepcid, Pulmicort, Regaine, Sudafed, and Visine/Vispring/Visclear brands. Kenvue Inc. was incorporated in 2022 and is headquartered in Summit, New Jersey.
FAQ
Is KVUE financially healthy?
Kenvue Inc.'s Piotroski F-score is 5/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the grey zone.
Does KVUE pay a dividend, and is it safe?
Yes. Kenvue Inc. pays a dividend yielding about 4.30% with a 107.6% payout ratio, rated “at-risk” for safety.
How profitable is KVUE?
In FY2025, Kenvue Inc. had a net margin of 9.7% and a return on equity of 13.7%.
What is KVUE's P/E ratio?
Kenvue Inc.'s trailing price-to-earnings (P/E) ratio is about 25.0×, based on its latest annual earnings.
What is the analyst price target for KVUE?
The average Wall-Street price target for Kenvue Inc. is $19.50, about 2.7% above the recent price, from 12 analysts (consensus: hold).
Is KVUE a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Kenvue Inc.: a Piotroski F-score of 5/9, an Altman Z″ in the grey zone, a P/E of about 25.0×, a dividend yield of 4.30%. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-28. Facts plus Stocktoria's own computed scores — not investment advice.